Acute lymphoblastic leukemia (ALL) is a rapidly progressing type of leukemia characterized by a variety of symptoms, including sudden onset of weakness, fatigue, bleeding, fever, infection, joint and bone pain, and hiccups. Treatment is long-term and requires patience for both patients and their families.

The primary goal in treating acute lymphoblastic leukemia is to reduce the proportion of leukemia cells (blasts) in the bone marrow from more than 20% at diagnosis to 5%. The second goal is to eliminate the invisible tumor burden, known as "minimal residual disease."

This type of leukemia is characterized by the sudden appearance of lymphoblasts, which form lymphocytes, a subtype of white blood cell, and their rapid proliferation in the blood and bone marrow. Genetic mutations in these cells lead to leukemia. The term "acute" refers to the sudden onset of this type of leukemia, its rapid progression if left untreated, and its potential to be fatal within a few months. Treatment requires a multidisciplinary approach and typically includes chemotherapy, radiation therapy, and bone marrow transplantation.

Causes and risk factors of acute lymphoblastic leukemia (ALL)

The emergence and progression of acute lymphoblastic leukemia (ALL) are caused by sequential genetic mutations that alter cellular functions. These mutations cause lymphoblasts, the primary cells of lymphocytes, to develop poorly and gain the ability to proliferate excessively, which in turn inhibits the production of other blood cells in the bone marrow.

The causes and risk factors of Acute Lymphoblastic Leukemia (ALL) can be generally listed as follows:

• Environmental factors such as exposure to ionizing radiation, chemical exposure, and previous viral infections.
• Rare cases of familial transmission. Having a family member previously diagnosed with ALL may increase the risk.
• Babies born with high birth weight have an increased risk of developing ALL, especially in the first 5 years of life.
• Individuals with Down syndrome have an increased risk of developing ALL.

Although there is no single, definitively proven cause of Acute Lymphoblastic Leukemia, it is known that these factors may increase the risk of the disease.

Frequency and epidemiology of acute lymphoblastic leukemia (ALL)

Acute lymphoblastic leukemia (ALL) is a rare disease. Its annual incidence typically ranges from 1 to 3 per 1 million people. The disease is more common in men than in women. It is also more common in children than in adults.

The most common age range for children is between 1 and 9 years old. Acute lymphoblastic leukemia is particularly common in this age group. In adults, it is more common between the ages of 20 and 60.

Epidemiological data show that the prevalence of acute lymphoblastic leukemia varies by age, gender, and geographic location. These data suggest that the disease varies across different populations based on various factors.

Acute lymphoblastic leukemia (ALL) symptoms and signs

Acute lymphoblastic leukemia is a type of leukemia that progresses rapidly, and symptoms usually appear suddenly. Even if patients had no symptoms a week prior, their blood counts may deteriorate and various symptoms may appear within a week. Therefore, the following symptoms should be taken into consideration:

• Weakness and fatigue: Leukemia cells that invade the bone marrow can disrupt red blood cell production and lower hemoglobin levels. This can cause symptoms such as weakness, fatigue, shortness of breath, and palpitations.
• Bleeding : Leukemia cells can interfere with platelet production, leading to a bleeding tendency. Symptoms include bleeding gums, nosebleeds, and bruising.
• Fever, infection, and inflammation: Leukemia can affect the immune system, reducing resistance to infection. Symptoms such as fever, sore throat, and cough may occur.
• Cough, hiccups, shortness of breath : These symptoms may occur when acute lymphoblastic leukemia spreads to the lungs or enlarges the lymph nodes in the chest cavity.
• Enlarged liver, spleen, or lymph nodes: Leukemia cells can affect these organs, causing swelling and pain in the abdomen.
• Headache, dizziness, loss of balance: The spread of leukemia cells to the nervous system or spinal cord can cause symptoms such as headache and loss of balance.
• Joint and bone pain: Leukemia that affects the bone marrow can cause joint and bone pain.
• Swelling in the genital organs: In male patients, swelling may occur in the genital area as a result of testicular involvement.
• Abdominal pain, constipation, nausea, vomiting: In rare cases, leukemia can spread to the gastrointestinal system and cause these symptoms.

If one or more of these symptoms occur, it is important to contact a healthcare professional and perform a detailed evaluation.

How is acute lymphoblastic leukemia (ALL) diagnosed?

Acute lymphoblastic leukemia (ALL) is usually diagnosed through a series of tests and evaluations. Some common methods used to diagnose ALL include:

• Medical history: The doctor evaluates the patient's health history, symptoms, family history, and information about previous treatments.
• Physical examination: A physical examination checks the patient's general health and organs such as the lymph nodes, spleen, and liver. This helps assess the extent of the disease and its impact on the organs.
• Complete blood count (CBC): A blood sample is taken to measure the number of red blood cells, white blood cells, and platelets. In ALL, the white blood cell count is usually high, but the functionality of normal white blood cells is impaired.
• Blood biochemistry: Liver and kidney function, as well as electrolyte balance, are assessed by measuring blood biochemical parameters. Some symptoms of ALL may become apparent in these tests.
• Peripheral blood smear: A blood sample is examined under a microscope to assess the shape and size of white blood cells, red blood cells, and platelets. Leukemia cells can be detected.
• Bone marrow aspiration and biopsy: Bone marrow is examined using a needle, usually taken from the pelvis. This procedure allows the bone marrow cells to be evaluated under a microscope and can detect the presence of leukemia cells.
• Genetic and molecular analyses: These tests, performed to understand the genetic structure of ALL, can be important in determining the subtypes of the disease and guiding treatment.
• Immunohistochemistry: This test is used to identify leukemia cells by examining certain antigens found on the surface of bone marrow cells.
• Flow cytometry: This test detects leukemia cells by measuring certain proteins and markers on the cell surface.

The diagnostic process typically involves a combination of these tests and is led by a hematologist or oncologist. Once a patient's diagnosis is determined, a treatment plan is developed.

Diagnostic algorithm applied in the diagnosis of acute lymphoblastic leukemia (ALL)

Patient evaluation:

• The patient's medical history is taken.
• With a physical examination, general health status, lymph nodes, spleen and liver are checked.

Blood tests:

• A complete blood count (CBC) measures the number of red blood cells, white blood cells, and platelets.
• Liver and kidney functions are evaluated with blood biochemistry.
• The general health of the organism is assessed by measuring the levels of certain substances contained in the blood.

Peripheral blood smear:

• The blood sample is examined under a microscope.
• The presence of leukemia cells (blasts) and their morphological features are evaluated.

Bone marrow aspiration and biopsy:

• The sample taken from the pelvic bone is used for morphological and microscopic examination of bone marrow cells.
• Bone marrow cells are evaluated for the presence, type, and spread of leukemia cells.

Genetic and molecular analyses:

• The genetic structure of leukemia cells is examined.
• Subtypes and genetic characteristics of the disease are determined.
• It helps with treatment planning and prognosis.

Immunohistochemistry and flow cytometry:

• Analysis of antigens found on the surface of bone marrow cells is performed.
• Used for the identification and characterization of leukemia cells.

Diagnostic and prognostic evaluation:

• Bone marrow blast ratio is evaluated.
• The genetic characteristics of the disease are determined through genetic analysis and other tests.
• The diagnosis is confirmed by a detailed evaluation that includes the patient's leukemia type, subtype and genetic profile.

This diagnostic algorithm consists of multiple stages to accurately diagnose the disease and develop a treatment plan. Hematologists and oncologists carefully follow these stages to best assess the patient's condition and determine appropriate treatment strategies.

Acute lymphoblastic leukemia (ALL) subtypes and classification

Acute lymphoblastic leukemia (ALL) can be divided into two immunological subtypes based on the surface antigens of the leukemia cells called lymphoblasts and into different subtypes based on genetic characteristics:

B-cell acute lymphoblastic leukemia (B-ALL):

• This subtype arises from the fact that leukemia cells have similar properties to B cells according to their surface antigens (immunophenotype).
• B-ALL is the most common subtype in childhood and adults.
• Subtyping is usually based on cellular and genetic characteristics.

T-cell acute lymphoblastic leukemia (T-ALL):

• This subtype arises from the fact that leukemia cells exhibit properties similar to T cells with respect to their surface antigens.
• It is less common than B-ALL, but can occur in children and young adults.
• T-cell leukemias are generally more aggressive and may have different genetic changes.

Genetic subtypes:

• B-ALL and T-ALL can be divided into genetic subtypes.
• For example, Philadelphia chromosome positive (Ph+) ALL has subtypes with genetic alterations such as the MLL gene translocation.
• Genetic analysis plays an important role in determining the subtype and prognosis of a patient's leukemia.

Subtyping:

• Different subtyping within B-ALL and T-ALL is based on cellular characteristics, genetic mutations, and cell surface antigens.
• These subtypes can help better understand the disease and determine the treatment plan.

This classification reflects the heterogeneous nature of acute lymphoblastic leukemia, allowing for personalization of treatment strategies and more effective assessment of patient prognoses.

Acute lymphoblastic leukemia (ALL) treatment and approaches

Treatment for acute lymphoblastic leukemia (ALL) involves a series of steps, depending on the patient's condition, and requires a multidisciplinary approach. The treatment process typically consists of the following stages:

• Remission induction therapy: This phase involves treatment to put the disease into remission. Chemotherapy, smart drugs, and sometimes steroids may be used. This process aims to reduce the number of leukemia cells in the bone marrow below the target level. It usually takes about a month for the bone marrow to regenerate normal cells.
• Central nervous system-sparing treatment: ALL can also affect the central nervous system. Therefore, if a patient has a condition that poses a risk of spreading the disease to the central nervous system, treatments such as chemotherapy or cranial radiotherapy may be used.
• Consolidation therapy: Once remission is achieved, consolidation therapy is used to further reduce the leukemia cells and maintain remission. This treatment usually includes chemotherapy and sometimes a stem cell transplant.
• Maintenance therapy: Maintenance therapy is a phase administered to patients in low-risk groups. After consolidation therapy is completed, patients are typically treated with oral medications and monthly intravenous chemotherapy. This phase typically lasts two years.
• Minimal residual disease monitoring: After treatment, regular follow-up and testing are necessary to prevent disease return and keep minimal residual disease under control.

Treatment may vary depending on the patient's overall health and the type and stage of leukemia. The most appropriate treatment plan for each patient should be determined by a hematologist or oncologist. Communication and support with the patient and their family are crucial throughout the treatment process, and collaboration with the healthcare team is crucial for managing potential side effects.

What is the survival time in acute lymphoblastic leukemia?

The survival of patients with acute lymphoblastic leukemia (ALL) varies depending on many factors. Survival rates vary depending on the patient's age, risk group, ALL subtype, response to treatment, and whether or not a transplant is possible.

Studies have shown 5-year survival rates generally range from 20% to 65%. These rates can vary depending on how well patients respond to treatment, the presence of minimal residual disease, and other factors.

A complete cure is generally considered in ALL patients who remain disease-free for five years. However, success in this process can vary depending on the specific characteristics of the disease and response to treatment.

It's important to regularly monitor patients throughout the treatment process and focus on supportive therapies to improve their quality of life. Furthermore, post-treatment follow-up should include regular checkups to monitor disease recurrence and identify potential complications early. Therefore, it's important to develop an individualized treatment plan for each patient and provide support to the patient and their family throughout the treatment process.